Proteomics

Dataset Information

0

Phospho-proteomic analysis of palmitate (PA)-treated L02 cells w/wo sorafenib treatment


ABSTRACT: Label-free based phospho-proteomic was used to analysis protein phosphorylation profile of L02 hepatocytes with or without 0.5 mM PA stimulate in condition of DMSO or 10 μM sorafenib for 18h

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Hepatocyte, Liver

DISEASE(S): Non-alcoholic Steatohepatitis

SUBMITTER: Xu Cheng  

LAB HEAD: Hongliang Li

PROVIDER: PXD018214 | Pride | 2022-08-30

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
P180088_B_AS1.raw Raw
P180088_B_AS2.raw Raw
P180088_B_AS3.raw Raw
P180088_B_PA1.raw Raw
P180088_B_PA2.raw Raw
Items per page:
1 - 5 of 13
altmetric image

Publications


Nonalcoholic steatohepatitis (NASH) is becoming one of the leading causes of hepatocellular carcinoma (HCC). Sorafenib is the only first-line therapy for advanced HCC despite its serious adverse effects. Here, we report that at an equivalent of approximately one-tenth the clinical dose for HCC, sorafenib treatment effectively prevents the progression of NASH in both mice and monkeys without any observed significant adverse events. Mechanistically, sorafenib's benefit in NASH is independent of it  ...[more]

Similar Datasets

2020-09-17 | PXD021081 | Pride
2024-10-31 | PXD052475 | Pride
2019-09-30 | PXD007640 | Pride
2023-06-29 | PXD042660 | Pride
2024-10-17 | PXD045214 | Pride
2022-02-17 | PXD026447 | Pride
2024-01-04 | PXD035954 | Pride
2008-12-30 | E-GEOD-14039 | biostudies-arrayexpress
2009-06-29 | E-GEOD-13299 | biostudies-arrayexpress
2018-07-16 | PXD009352 | Pride